AbCellera Biologics Inc. · NASDAQ:ABCL

AbCellera Biologics — Q3 2026 Earnings Presentation

25 slides from AbCellera Biologics's earnings presentation, Nov 9, 2026

Slide 2: Disclaimer
DISCLAIMER This document contains forward-looking statements, including statements made pursuant These statements involve risks, uncertainties and other factors that may cause to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. actual results, levels of activity, p
Slide 3: Phase 2 data demonstrate ABCL635 has potential to redefine standard of care for VMS
Phase 2 data demonstrate ABCL635 has potential to redeﬁne the standard of care for treating vasomotor symptoms Positive top-line ABCL635 Phase 2 data at week 4 demonstrate a new efficacy benchmark for reducing the frequency and severity of moderate and severe vasomotor symptoms (VMSM-S) Q3 2026 Busi
Slide 4: ABCL635 reduced the frequency of moderate and severe VMS starting at week 1
ABCL635 reduced the frequency of moderate and severe VMS starting at week 1 through week 4 Frequency of Moderate and Severe VMSM-S Primary MMRM analysis Sensitivity MMRM analysis ● Mean placebo-adjusted treatment difference of 2.6 at week 1 Q3 2026 Business Update ● Mean placebo-adjusted treatment d
Slide 5: ABCL635 reduced the severity score of moderate and severe VMS
ABCL635 reduced the severity score of moderate and severe VMS starting at week 1 through week 4 Severity Score of VMSM-S Primary MMRM analysis Sensitivity MMRM analysis ● Mean placebo-adjusted treatment difference of 0.3 at week 1 Q3 2026 Business Update ● Mean placebo-adjusted treatment difference
Slide 6: ABCL635 participants fared better than placebo across all threshold values
ABCL635 participants fared better than placebo across all threshold values Cumulative Distribution at Week 4 of VMSM-S Frequency and Severity Scores VMS Frequency VMS Severity Q3 2026 Business Update % Reduction from ABCL635 (N=46) Placebo (N=46) % Reduction from ABCL635 (N=46) Placebo (N=46) baseli
Slide 7: ABCL635 efficacy markedly improved compared to approved NK3R antagonists at week 4
ABCL635 Phase 2 efficacy data are markedly improved compared to approved small molecule NK3R antagonists at week 4 VMSM-S Frequency and Severity Placebo-Adjusted Change from Baseline at Week 4* Frequency Severity Q3 2026 Business Update ABCL635 SC 600 mg ABCL635 SC 600 mg Fezolinetant 45 mg -Trial 1
Slide 8: ABCL635 was well tolerated, with no gastrointestinal or liver signals
ABCL635 was well tolerated, with no gastrointestinal or liver signals Adverse Events (AEs) reported in at least two patients in either group regardless of relationship during ﬁrst 4-weeks of treatment ABCL635 (600 mg) Placebo ● No SAEs or severe (Grade 3+) AE Preferred Term Once Monthly, SC (N=46) O
Slide 9: Following positive Phase 2 data, advancing ABCL635 into multiple indications
Following the positive Phase 2 data, we are advancing ABCL635 into multiple indications Menopause New Indications Q3 2026 Business Update In discussions with regulators and Expect to advance ABCL635 in 2027 working through the FDA’s MIDD for VMSM-S due to: program to advance ABCL635 for VMSM-S ● Adj
Slide 10: We are also advancing a new program, ABCL992
We are also ABCL992 is a next-gen half-life extended analog of ABCL635 advancing a new Q3 2026 Business Update program, ABCL992, ● Designed to supports less frequent dosing for the treatment ● Currently in IND-enabling of VMSM-S activities COPYRIGHT © ABCELLERA 10 VMSM-S: moderate and severe VMS.
Slide 11: ABCL575 is an investigational antibody targeting OX40 ligand
ABCL575 ABCL575 is an investigational antibody targeting OX40 ligand AbCellera currently does not intend to develop ABCL575 past Phase 1. Q3 2026 Business Update Target OX40 Ligand (OX40L) Indications Atopic Dermatitis (AD), Autoimmune Diseases Therapeutic Area Immunology & Inﬂammation Status COPYRI
Slide 12: ABCL575-101: first-in-human Phase 1 study in healthy participants
ABCL575-101: A ﬁrst-in-human Phase 1 study in healthy participants Phase 1 SAD Trial Design A FIH Phase 1 randomized, double-blind, single ascending dose study of ABCL575 in Q3 2026 Business Update healthy participants Participants N=40 NHV, 18-65 year old N=8 per cohort, 6 active, 2 placebo (3:1 ra
Slide 13: Demographic and baseline characteristics
Demographic and baseline characteristics Treatment groups were generally balanced ABCL575 (Cohorts A1-A5) (N=30) Pooled Overall SAD Population Placebo (N=40) (N=10) Q3 2026 Business Update 75 mg 150 mg 300 mg 600 mg 900 mg (N=6) (N=6) (N=6) (N=6) (N=6) Age (median, years) 33.0 40.0 58.5 41.0 36.5 51
Slide 14: ABCL575 demonstrates a favorable tolerability profile
ABCL575 demonstrates a favorable tolerability proﬁle Adverse Events (AEs) reported in at least two participants in either group regardless of relationship ABCL575 ● Favorable (Cohorts A1-A5) Total Pooled placebo preliminary safety Adverse Event Preferred Term ABCL575 (N=10) (N=30) proﬁle across all
Slide 15: ABCL575 exhibited sustained exposure with mean half-life of 65 days
ABCL575 exhibited sustained exposure with a mean half-life of 65 days supportive of Q12W or longer dosing Pharmacokinetics ● Approximately dose proportional exposure SAD PK ● Mean half-life of ~65 days ranging from Q3 2026 Business Update 43 days in cohort A1 to 79 days in cohort A4, as predicted fr
Slide 16: ABCL575 Phase 1 study met its endpoints
ABCL575 Phase 1 study met its endpoints SAFETY/TOLERABILITY ENDPOINT PHARMACOKINETIC ENDPOINT Favorable preliminary tolerability PK proﬁle supports an extended proﬁle dosing interval Q3 2026 Business Update All doses tested in the 75 to 900 mg range were well Estimated half-life of ~65 days tolerate
Slide 17: Completed $200M oversubscribed capital raise
Number of shares and pre-funded warrants ~20M common shares Completed $200M Q3 2026 Business Update oversubscribed Share price & pre-funded warrant price $9.75 per share capital raise Transaction closed August 14, 2026 COPYRIGHT © ABCELLERA 17
Slide 18: AbCellera Programs
ABCELLERA PROGRAMS PROGRAMS TARGET INDICATION THERAPEUTIC AREA STAGE IND-Enabling Phase 1 Phase 2 Phase 3 VMS due to Endocrinology menopause & Women’s Health VMS due to breast ABCL635 NK3R cancer treatment Oncology Q3 2026 Business Update VMS due to prostate Oncology cancer treatment ABCL992 NK3R VM
Slide 19: 2026 Priorities
2026 PRIORITIES We advanced ABCL992, ABCL385, and ABCL646 into the pipeline, completing all 2026 priorities Q3 2026 Business Update ABCL635 Phase 2 clinical trial ABCL688 progressing through Nominate at top-line readout on Aug 10, 2026 IND-enabling activities least 1 additional development candidate
Slide 21: We continue to maintain a strong liquidity position
We continue to >$790M in total cash balances & marketable securities* maintain a strong Q3 2026 Business Update liquidity position >$100M in total available to execute on our government funding* strategy >$890M in available liquidity to execute on our strategy* COPYRIGHT © ABCELLERA * As of Septembe
Slide 22: Revenue and Operating Expenses
Revenue USD Operating Expenses USD LICENSING AND ROYALTY RESEARCH & SALES, GENERAL & MILESTONES DEVELOPMENT ADMIN RESEARCH FEES Q3 2026 Business Update +$6.8M $46.0M $39.2M -$8.1M $22.0M $17.1M $13.9M $4.1M COPYRIGHT © ABCELLERA Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025 Q2 2026 22

AbCellera Biologics — Q3 2026 Earnings Presentation on 6ix

AbCellera Biologics — Q3 2026 Earnings Presentation

Slide 1: Q3 2026 Business Update

Slide 2: Disclaimer

Slide 3: Phase 2 data demonstrate ABCL635 has potential to redefine standard of care for VMS

Slide 4: ABCL635 reduced the frequency of moderate and severe VMS starting at week 1

Slide 5: ABCL635 reduced the severity score of moderate and severe VMS

Slide 6: ABCL635 participants fared better than placebo across all threshold values

Slide 7: ABCL635 efficacy markedly improved compared to approved NK3R antagonists at week 4

Slide 8: ABCL635 was well tolerated, with no gastrointestinal or liver signals

Slide 9: Following positive Phase 2 data, advancing ABCL635 into multiple indications

Slide 10: We are also advancing a new program, ABCL992

Slide 11: ABCL575 is an investigational antibody targeting OX40 ligand

Slide 12: ABCL575-101: first-in-human Phase 1 study in healthy participants

Slide 13: Demographic and baseline characteristics

Slide 14: ABCL575 demonstrates a favorable tolerability profile

Slide 15: ABCL575 exhibited sustained exposure with mean half-life of 65 days

Slide 16: ABCL575 Phase 1 study met its endpoints

Slide 17: Completed $200M oversubscribed capital raise

Slide 18: AbCellera Programs

Slide 19: 2026 Priorities

Slide 20: Q3 2026 Financials Update

Slide 21: We continue to maintain a strong liquidity position

Slide 22: Revenue and Operating Expenses

Slide 23: Earnings

Slide 24: Cash Flows

Slide 25: Thank You